Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The latest biotechnology company hoping to get genetic ...

Following a gift from Brown trustee Giammaria Giuliani P’28 and Sabrina Giuliani P’28, Brown’s RNA center will be named the ...

Lethal and rescuer genes are defined as genes that when inactivated result in cell death or enhanced cell growth, respectively. The ability to identify these genes in large-scale automated screening ...

New York, May 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global RNA Interference Technology Market - Premium Insight, Competitive News Feed Analysis, Company ...

SNS Insider report highlights a CAGR of 14.68% from 2025–2032 as RNAi emerges as a transformative force in biotechnology, precision medicine, and agricultural innovation.Austin, Nov. 03, 2025 (GLOBE ...

RNA interference (RNAi) offers a fast and easy system to study gene functions. However, the traditionally used small interfering RNAs (siRNAs) can exhibit pronounced and problematic off-target effects ...

SAN FRANCISCO (AP) _ The biotechnology field is littered with the debris of would-be miracle cures. These days, the buzz is building around a technology called ``RNA interference,'' whose legions of ...